New Evidence of Sanbexin^® in AIS treatment Published During ESOC 2022

Simcere Completes Patient Enrollment for Phase 3 Registrational Study of Sanbexin Sublingual Tablet

New targets for AD, cancer and COVID19 therapy revealed at Simcere Innovation Forum 2021

Envafolimab and Trilaciclib Included in 4 Updated CSCO 2022 Guidelines

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day

Simcere’s oral PRMT5 inhibitor featured in an oral presentation of AACR annual meeting

Simcere Appoints Andrew Zhu as Senior Vice President in Charge of Sales and Marketing

SIMCERE PHARMA (HK.2096) to Host 2022 R&D Day

New Dosage Form for Backbone Chemotherapy! Docetaxel Polymeric Micelles Achieved FPI in Phase 2 Clinical Trial

Simcere Announces Appointment of Dr. Danny Chen as Senior Vice President